Research presented at AAAAI 2026 suggests GLP-1 RAs may provide clinical benefits for asthma management in patients with excess body weight.

Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.

Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 AAAAI Annual Meeting.

A survey of Scripps Health clinicians reveals that specialty and personal risk assessment of side effects drive the chronic cough treatment gap.

Biologic therapy during pregnancy was not associated with adverse outcomes for most patients in a retrospective study presented at AAAAI 2026.

Patients with hereditary angioedema report significant unmet needs, including high costs and insurance barriers, according to data from AAAAI 2026.

Novo Nordisk announced Tuesday that it will cut US list prices of Ozempic and Wegovy by up to 50% starting next year. The lower prices will take effect January 1, 2027, the same time that reduced ...

A retrospective cohort study of 210,000 pediatric patients showed ICS therapy did not elevate the risk for pediatric fractures.

Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 inflammation.

HealthDay News — A measles outbreak at a private college in southwest Florida is raising new concerns about how quickly the ...

Phase 3 trial results demonstrate the superiority of long-acting injectable cabotegravir + rilpivirine over daily oral ...

The data suggest significant challenges in maintaining long-term disease control with advanced systemic therapies for atopic dermatitis.